Where Will KRAS Drug Discovery Be Beyond 2027? Player Map and 5 Reshuffling Scenarios | KRAS Frontier Vol.3 (Final)

Key Points

• By 2026, KRAS drug discovery is competing across three modality axes (small-molecule inhibitors — mutation-specific / pan-RAS / degraders; upstream modulators — SHP2 / SOS1 / RAF; and immunotherapies — mRNA vaccines / TCR-T / BiTE) and two camps (Big Pharma and biotechs).
• The clear 2026 leader is Revolution Medicines (pan-RAS daraxonrasib, G12D zoldonrasib). Amgen (sotorasib + LumiAtlas) and BMS (adagrasib + the Mirati portfolio) follow. From 2027 onward, next-generation G12V / G13D / Q61-specific drug readouts arrive in waves.
• Strategic axes: (1) indication expansion (NSCLC → CRC → PDAC → biliary → endometrial → rare cancers); (2) shift to 1L / adjuvant / neoadjuvant; (3) combinations (ICI, anti-EGFR, SHP2/SOS1, chemo, vaccines); (4) diagnostic linkage (NGS, ctDNA); (5) resistance sequencing.
• 2027-2030 outlook: PDAC 1L may pivot to daraxonrasib-centric regimens; NSCLC 1L sees adagrasib + ICI as a new standard; CRC adopts KRAS + EGFR combinations; personalized mRNA vaccines establish in PDAC/melanoma adjuvant therapy. KRAS-driven cancer prognosis and treatment frameworks face fundamental restructuring.

Introduction — From “Undruggable” to “Most Active Target”

As Vol.1 and Vol.2 established, KRAS reversed its status from the archetypal “undruggable” target to one of the most active new-drug fields of 2026. A field that stalled for ~30 years was rewritten in roughly 12 years: Shokat’s 2013 discovery → sotorasib’s 2021 approval → daraxonrasib / zoldonrasib’s 2025-26 breakthroughs.

This article maps the player landscape and projects the 2027-2030 outlook.

Body

1. Player Map Overview — 3 Axes × 2 Camps

Table 1: Major KRAS drug-discovery players (2026)

Category	Big Pharma	Biotechs
G12C inhibitors	Amgen (sotorasib), BMS (adagrasib), Roche (divarasib / GDC-6036), Eli Lilly (LY3537982)	Multiple me-too candidates
G12D / pan-RAS / degraders	Eli Lilly (LY3962673, G12D PROTAC)	Revolution (daraxonrasib, zoldonrasib), BridgeBio Oncology, Frontier Medicines, Erasca, Black Diamond
SHP2 inhibitors	Novartis (TNO155), Roche (migoprotafib / RG6433)	Revolution (RMC-4630), BridgeBio (BBP-398), Jacobio (JAB-3068), Erasca (ERAS-601)
SOS1 inhibitors	Boehringer Ingelheim (BI 1701963)	Mirati lineage (MRTX0902)
RAF inhibitors	Novartis (pan-RAF), Roche	Day One Biopharmaceuticals (tovorafenib)
mRNA / neoantigen vaccines	—	BioNTech (autogene cevumeran), Moderna (mRNA-4157 / V940)
TCR-T, BiTE	—	Adaptimmune, Immatics, others

2. Leader: Revolution Medicines

The clear 2026 leader is Revolution Medicines (NASDAQ: RVMD; ~$10B market cap; Redwood City, CA).

Pipeline:

• Daraxonrasib (RMC-6236): pan-RAS multi-selective; Phase 3 PDAC (previously treated) success; advancing in 1L PDAC, NSCLC, and CRC.
• Zoldonrasib (RMC-9805): G12D-selective; Phase 3 launching in PDAC and NSCLC.
• Elironrasib (RMC-6291): G12C-selective (next generation), RAS(ON) mechanism, Phase 1/2.
• RMC-7977: pan-RAS multi-selective (preclinical), aiming for broader coverage than daraxonrasib.
• RMC-4630: SHP2 inhibitor — complementary KRAS combination.

The strategic core is the RAS(ON) platform: cyclophilin-A-bridged tri-complex chemistry that binds active GTP-bound RAS — distinct from sotorasib/adagrasib OFF-state targeting. The platform supports designs from mutation-selective to multi-selective, enabling multiple products from one chemistry.

Partnerships and capital: a multi-billion-dollar strategic partnership with Sanofi, prior collaboration with Pfizer, and a strong cash position via NASDAQ listing.

3. Big Pharma — Amgen, BMS, Roche, Lilly, Boehringer

Amgen (sotorasib):

• Continued strengthening of Lumakras monotherapy and combinations.
• LumiAtlas platform: in-house second-generation KRAS inhibitors.
• The CodeBreaK trial family delivers multiple combination strategies.
• Strategic transition from FDA accelerated approval to full approval.

BMS (formerly Mirati):

• Krazati (adagrasib) indication expansion.
• KRYSTAL trial family (KRYSTAL-7, etc.).
• Post-2024 Mirati acquisition strategic integration ongoing.
• SOS1 inhibitor MRTX0902, PRMT5 inhibitors, and G12D candidates in the broader portfolio.

Roche (Genentech):

• Divarasib (GDC-6036): G12C inhibitor with NSCLC Phase 1/2 ORR ~53%, potentially exceeding sotorasib/adagrasib.
• Combinations with Roche SHP2 inhibitor migoprotafib.
• Part of Genentech’s broader oncology portfolio.

Eli Lilly:

• LY3537982: next-generation G12C inhibitor.
• LY3962673: G12D PROTAC degrader, Phase 1.
• Leveraging Loxo Oncology’s precision-medicine platform internally.

Boehringer Ingelheim:

• BI 1701963: SOS1 inhibitor; Phase 1/2 in KRAS combinations.
• Private and less publicly visible, but advancing steadily in the KRAS-adjacent space.

4. Mid-Cap Biotechs — BridgeBio Oncology, Frontier, Erasca, Black Diamond

BridgeBio Oncology Therapeutics (BridgeBio Pharma subsidiary):

• BBO-8520: variant-specific inhibitors for G12C / G12D / G12V (preclinical / Phase 1).
• BBP-398: SHP2 inhibitor (in-licensed from BMS).
• “Mutation-specific portfolio” strategy.

Frontier Medicines:

• Covalent-chemistry platform yielding KRAS variant inhibitors.
• Targeting challenging mutations (G12V, Q61).
• Series D financing in 2024.

Erasca:

• ERAS-601: SHP2 inhibitor.
• Building a RAS-MAPK pathway portfolio.

Black Diamond Therapeutics:

• “Allosteric driver” approach via the MAP platform.
• Initial focus on EGFR variants; KRAS expansion underway.

5. mRNA Vaccine Camp — BioNTech and Moderna

Both leveraged COVID-vaccine success to expand into oncology.

BioNTech autogene cevumeran:

• Personalized neoantigen mRNA vaccine (up to 20 neoepitopes).
• PDAC adjuvant Phase 1 (NEJM 2023, Balachandran et al., MSK): vaccine responders showed dramatically improved RFS.
• Phase 2 expansion underway.
• Co-developed with Genentech.
• Covers many neoantigens, including KRAS variants.

Moderna mRNA-4157 (V940):

• Personalized neoantigen vaccine (up to 34 neoepitopes).
• Melanoma adjuvant Phase 2 (KEYNOTE-942): pembrolizumab + V940 improved RFS by 44% versus pembrolizumab alone.
• Co-developed with Merck.
• Expanding into NSCLC, RCC, muscle-invasive bladder cancer.

Because these vaccines cover the full neoantigen repertoire including KRAS variants, their mechanism is complementary to KRAS-specific small molecules (e.g., zoldonrasib), enabling theoretically strong combinations. PDAC adjuvant Phase 3 readouts are expected in 2027-2028.

6. TCR-T, BiTE, and Cell Therapy

• Adaptimmune: affinity-engineered TCR-T cells targeting KRAS neoantigens.
• Immatics: TCR bispecifics (IMA401, IMA402) and TCR-T trials targeting KRAS G12V / G12D peptides.
• Lyell Immunopharma: epigenetic T-cell reprogramming for durability — KRAS-targeting cell therapy.
• Iovance Biotherapeutics: TIL therapy approved in melanoma; expansion into KRAS-driven cancers under consideration.

7. Diagnostic Tool Linkage — NGS, ctDNA, Cancer Interceptors

Clinical implementation requires precision diagnostics:

• FoundationOne CDx (Roche / Foundation Medicine): FDA-approved comprehensive tumor NGS — the standard for KRAS variant identification.
• Guardant360 CDx (Guardant Health): liquid-biopsy NGS for ctDNA-based KRAS detection — therapy decisions and resistance monitoring.
• Tempus xT: comprehensive genomic profiling plus AI-based therapy recommendations.
• Caris Molecular Intelligence: multi-omics analysis.
• GRAIL Galleri: multi-cancer early detection (MCED) — earlier detection of relevant cancers.

Companion-diagnostic (CDx) partnerships between these diagnostics and KRAS therapy companies are pivotal for indication expansion and clinical penetration.

8. Five Predictions for 2027-2030

1. PDAC 1L standard shift: from FOLFIRINOX/GnP-only to daraxonrasib (or zoldonrasib + chemo)-centric. Phase 3 1L readouts in 2027-28 will determine pace. PDAC median OS may extend to 11-15 months.
2. NSCLC 1L: adagrasib + pembrolizumab as new standard. KRYSTAL-7 expansion success would reshape KRAS G12C+ NSCLC SOC. PD-L1 ≥50% likely retains 60%+ ORR.
3. CRC: KRAS-EGFR combinations spread. Sotorasib + panitumumab / adagrasib + cetuximab become 2L standards in KRAS G12C+ CRC, with 1L exploration.
4. Personalized mRNA vaccines establish in PDAC and melanoma adjuvant. Approvals for autogene cevumeran / mRNA-4157 add a new pillar.
5. Resistance-sequencing standardization. Post-first-line rebiopsy → resistance profile → next-line choice (pan-RAS, SHP2, SOS1, ICI swap, vaccine) algorithms become formalized.

9. Outstanding Challenges

• Resistance management standardization: optimal sequencing, maintenance vs intermittent dosing.
• Toxicity management: WT RAS off-target effects of pan-RAS — GI and dermatologic.
• Non-hotspot variants: G12R, G12A, Q61.
• Surgical contexts: efficacy and safety in neoadjuvant / adjuvant.
• Pediatric and rare cancers: neuroblastoma, rhabdomyosarcoma, RAS-mutant cohorts.
• Diagnostic access: NGS / ctDNA in low/middle-income countries.
• Cost and reimbursement: $300-400K+ annual treatment costs and access equity.
• Complete resistance mechanism elucidation: unknown bypass, epigenetic, and microenvironment factors.

My Thoughts and Outlook

The KRAS journey is a textbook story of “undruggable to most-active in 12 years”: Shokat 2013 → sotorasib 2021 → sotorasib + panitumumab 2024 → daraxonrasib / zoldonrasib breakthroughs 2025-26. A near-linear progression marking a moment when “untreatable cancer” assumptions cede to technology and science.

First, 2027-2030 will be a fundamental restructuring period for PDAC therapy. PDAC’s 30-year prognostic stagnation is breaking through via the dual engine of KRAS inhibitors and mRNA vaccines — the largest structural shift in PDAC since surgical standardization in the 1980s-90s.

Second, NSCLC 1L combinations of KRAS inhibitor + ICI will mark KRAS G12C+ NSCLC as a leading-edge case of treatment evolution: ICI alone → ICI + chemo → targeted + ICI.

Third, personalized mRNA neoantigen vaccines stand alongside KRAS therapy as the next pillar. Phase 3 outcomes for autogene cevumeran and mRNA-4157 may fundamentally reshape adjuvant oncology.

Fourth, diagnostic-tool integration is decisive. Guardant360 CDx, FoundationOne CDx, and Tempus xT standardize therapy selection and resistance monitoring.

Fifth, the remaining variants (G12V, Q61) and adaptation expansion (adjuvant, pediatric, rare) form the next 5-10-year battlefield, where biotechs like BridgeBio Oncology and Frontier Medicines will fill the gaps.

This series has charted KRAS drug discovery’s “current location”. A long-untreatable disease class has begun moving toward treatability — the “moment of inflection” deserves attention.

Beginner’s Perspective

This final article maps the KRAS landscape. The four main types of drugs:

1. KRAS direct inhibitors (small molecules): Revolution Medicines, Amgen, BMS, Roche, Lilly.
2. Upstream regulators (SHP2, SOS1): Novartis, Boehringer, Revolution, BridgeBio.
3. KRAS degraders: MSK, Lilly.
4. KRAS vaccines (mRNA, personalized): BioNTech, Moderna.

The 2026 leader is Revolution Medicines. Daraxonrasib (broad coverage of KRAS variants) nearly doubled survival in pancreatic cancer; zoldonrasib (G12D-specific) keeps producing strong results.

Expected changes in 2027-2030: (1) pancreatic cancer treatment shifts from chemo-centric to KRAS-inhibitor-centric; (2) lung cancer (KRAS G12C) gets a new 1L standard — KRAS inhibitor + immunotherapy; (3) colorectal cancer adopts KRAS + EGFR antibody combinations more widely; (4) personalized mRNA vaccines start being used to prevent recurrence after surgery.

The phrase “untreatable cancer” is becoming a historical artifact. Not every cancer will be solved, but real progress is unmistakable and accelerating.

Science Writer’s View

By 2026 KRAS competition spans three modality axes (small-molecule inhibitors, upstream modulators, immunotherapies) and two camps (Big Pharma, biotech). The clear 2026 leaders are Revolution Medicines (daraxonrasib pan-RAS, zoldonrasib G12D, elironrasib next-gen G12C) and Amgen (sotorasib + LumiAtlas). BMS (adagrasib + Mirati integration), Roche (divarasib), Lilly (G12D PROTAC), Boehringer (SOS1), Novartis (SHP2), and Day One (pan-RAF) follow. The mRNA neoantigen vaccine front leads with BioNTech’s autogene cevumeran and Moderna’s mRNA-4157 in PDAC and melanoma adjuvant. TCR-T, BiTE, and TIL programs run in parallel. Companion-diagnostic linkage (FoundationOne CDx, Guardant360 CDx, Tempus xT, Caris, GRAIL Galleri) is decisive for clinical implementation. 2027-2030 outlook: PDAC 1L pivots to daraxonrasib-centric regimens; NSCLC 1L adopts adagrasib + ICI as new SOC; CRC sees widespread KRAS-EGFR combinations; personalized mRNA vaccines establish in PDAC/melanoma adjuvant; resistance-sequencing algorithms become standardized. Open issues: minor variants (G12R, G12A, Q61), neoadjuvant/adjuvant settings, pediatric and rare cancers, diagnostic access, pricing/reimbursement, and full resistance-mechanism elucidation.

Expert Perspective

2026 KRAS landscape: (A) Mutation-specific small molecules — sotorasib (Amgen, Lumakras), adagrasib (BMS, Krazati), divarasib (Roche, GDC-6036; NSCLC Phase 1/2 ORR ~53%), LY3537982 (Lilly, next-gen G12C), zoldonrasib (Revolution RMC-9805, G12D-selective), elironrasib (Revolution RMC-6291, G12C next-gen RAS-ON). (B) Pan-RAS — daraxonrasib (Revolution RMC-6236, multi-selective; Phase 3 RASolute 302 success), RMC-7977 (Revolution preclinical, broader coverage), BBO-8520 (BridgeBio Oncology, multi-variant portfolio). (C) Degraders — MSK first-in-class G12D PROTAC (Phase 1), Lilly LY3962673 (G12D PROTAC, Phase 1). (D) Upstream modulators — SHP2 (Novartis TNO155, Roche migoprotafib RG6433, Revolution RMC-4630, BridgeBio BBP-398, Jacobio JAB-3068, Erasca ERAS-601), SOS1 (Boehringer BI 1701963, BMS/Mirati MRTX0902), pan-RAF (Day One tovorafenib, Novartis), ERK (ulixertinib). (E) Immunotherapies — autogene cevumeran (BioNTech / Genentech, PDAC adjuvant Phase 2; NEJM 2023 Balachandran et al. responder benefit), mRNA-4157 / V940 (Moderna / Merck, KEYNOTE-942 melanoma adjuvant Phase 2, RFS +44%), TCR-T (Adaptimmune, Immatics), BiTE (Immatics IMA401/IMA402), TIL (Iovance). (F) CDx — FoundationOne CDx (Roche / Foundation Medicine), Guardant360 CDx (Guardant Health), Tempus xT, Caris Molecular Intelligence, GRAIL Galleri. Strategic axes: indication expansion (NSCLC → CRC → PDAC → biliary → endometrial → pediatric/rare), 1L / adjuvant / neoadjuvant migration, combinations (ICI, anti-EGFR, SHP2/SOS1, chemo, vaccines), diagnostic linkage, resistance sequencing. 2027-2030 outlook: PDAC 1L standard shift toward daraxonrasib- (or zoldonrasib + chemo-) centric regimens; NSCLC 1L with adagrasib + ICI as new SOC; CRC standardization of KRAS-EGFR combos; personalized mRNA vaccines in PDAC/melanoma adjuvant; resistance-sequencing algorithm standardization. Open challenges: resistance management standardization, toxicity (especially WT RAS off-target), minor variants (G12R, G12A, Q61), surgical contexts, pediatric/rare cancers, LMIC diagnostic access, cost/reimbursement equity, complete resistance-mechanism elucidation. KRAS reversed from undruggable to most active oncology target in 12 years since Shokat 2013 — 2026 deserves to be remembered as an inflection point.